Episode

Ep183: Sabah Oney on CAR-T Cells Against Solid Tumors

Podcast: The Long Run with Luke Timmerman
Published: Aug 6, 2025
Duration seconds: 3383
Processing state: not_requested
Canonical source: https://soundcloud.com/longrunpodcast/ep183-sabah-oney-on-car-t-cells-against-solid-tumors
Audio: https://feeds.soundcloud.com/stream/2148830682-longrunpodcast-ep183-sabah-oney-on-car-t-cells-against-solid-tumors.mp3
JSON: /v1/public/podcasts/the-long-run-with-luke-timmerman-1124799/episodes/ep183-sabah-oney-on-car-t-cells-against-solid-tumors
Markdown: /podcast/the-long-run-with-luke-timmerman-1124799/ep183-sabah-oney-on-car-t-cells-against-solid-tumors.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-long-run-with-luke-timmerman-1124799/episodes/ep183-sabah-oney-on-car-t-cells-against-solid-tumors/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-long-run-with-luke-timmerman-1124799/ep183-sabah-oney-on-car-t-cells-against-solid-tumors.md
Read the agent-friendly Markdown representation of this episode resource.

Sabah Oney, CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics, on engineering CAR-T cells that can kill solid tumors.